- NovoCure has developed and is commercializing a therapy for fast-growing and aggressive brain tumor using TTFields.
- Its product has reached maturity phase in core active markets, with an expansion in new geographies on the cards.
- The healthcare equipment play is investing heavily in research and obtaining the FDA's designation as a breakthrough device for liver cancer is a positive.
- There may be short-term volatility towards the end of this quarter as expansion plans take time to deliver and R&D expenses continue to increase.
- In view of opportunities to expand and financial capability to develop new uses for TTFields, the stock is a buy at current prices.
For further details see:
NovoCure: TTFields Generating Revenues And Creating Avenues For Further Growth